A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma (Q56898845)

2

0 references

John Powderly

3

0 references

Khuda D Khan

4

0 references

Anna C Pavlick

5

0 references

Lee D Cranmer

6

0 references

Wolfram E Samlowski

7

0 references

Geoffrey M Nichol

8

0 references

Michael J Yellin

9

0 references

Jeffrey S Weber

Investigational New Drugs

10

0 references

language of work or name

English

0 references

publication date

June 2011

0 references

published in

0 references

volume

29

0 references

page(s)

489-98

0 references

issue

3

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10637-009-9376-8

0 references

cites work

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Current systemic therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

The role of the CTLA4 blockade in the treatment of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Update on anti-CTLA-4 antibodies in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9376-8

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20082117

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20082117

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immunotherapy and chemotherapy--a practical partnership

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20082117